Search results
Showing 811 to 825 of 1835 results for carers
In development Reference number: GID-TA11694 Expected publication date: TBC
In development Reference number: GID-TA11130 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 18 February 2026.
This quality standard covers diagnosing and managing drug allergy in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS97Show all sections
Sections for QS97
- Quality statements
- Quality statement 1: Documentation using the structured assessment guide
- Quality statement 2: Advice about carrying personal structured drug information
- Quality statement 3: Referral to specialist drug allergy services
- Quality statement 4: Recording drug allergy status in electronic medical records
- Quality statement 5: Updating information on drug allergy status
- Quality statement 6 (developmental): Prescription information on drug avoidance
- About this quality standard
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]
In development Reference number: GID-TA11071 Expected publication date: TBC
Awaiting development Reference number: GID-TA11538 Expected publication date: TBC
PillCam COLON 2 for investigation of the colon through direct visualisation
In development Reference number: GID-DG10083 Expected publication date: TBC
In development Reference number: GID-TA11162 Expected publication date: 28 July 2027
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
In development Reference number: GID-TA11154 Expected publication date: TBC
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia
Awaiting development Reference number: GID-MT599 Expected publication date: TBC
Monofocal intraocular lenses for cataract surgery (provisional title)
In development Reference number: GID-HTE10090 Expected publication date: TBC
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor
In development Reference number: GID-IPG10441 Expected publication date: TBC
We are listening to your views on this Interventional procedures guidance. Comments close 11 February 2026.
Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.